From the publisher feed

GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned. GLP-1 blockbuster medications such as Novo Nordisk’s Ozempic and Eli Lill

Read the original at The Guardian ↗

Opens the original publisher page. Access, copyright and subscriptions are controlled by the publisher.

A useful next step

  1. Read the short publisher description here.
  2. Open the full report directly at the publisher.
  3. Compare this topic with other sources when useful.